Real-world outcomes of axi-cel treatment of large B-cell lymphoma
In this MEDtalk, Dr. Frederick L. Locke presents real-world evidence of axi-cel in the treatment of patients with large B-cell lymphoma. Focusing on the impact of age and comorbidity status on safety and efficacy outcomes after axi-cel infusion, Dr Locke highlights that even though age does not predict for worse efficacy of axi-cell, older patients (≥ 65 years) should be treated with caution, as they are more likely to have adverse events.
Få adgang til artiklen
Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.